CAJ | 학술논문

目的：观察口服胶原蛋白多肽对中老年女性膝骨关节炎患者关节疼痛和功能的临床效果。方法94例年龄（60.79±7.57）岁的中老年女性膝骨关节炎患者随机分成Peptan组46例和安慰剂组48例，分别服用胶原蛋白多肽（Peptan）8 g/d和麦芽糊精（安慰剂）8 g/d，连续服用3个月，应用WOMAC评分和Lysholm评分来评估服用前后骨关节炎症状和功能的改善状况。结果（1）WOMAC评分：服用前Peptan组和安慰剂组WOMAC评分差别无统计学意义（15.26±4.95与15.77±3.53，P＝0.565）；服用3个月后Peptan 组WOMAC评分明显减少到14.20±5.27（P＜0.001），而安慰剂组WOMAC评分15.79±3.53，与服用前差别无统计学意义（ P＝0.881）；服用前后两组WOMAC 评分变化趋势（差值）差别存在统计学意义（ P＜0.001）；（2）Lysholm评分：服用前Peptan组和安慰剂组评分差别无统计学意义（80.24±11.78 vs 78.96±9.90，P＝0.569）；服用3个月后Peptan组Lysholm评分明显增加到82.63±10.49（P＜0.001），而安慰剂组Lysholm评分79.21±9.79，与服用前差别无统计学意义（P＝0.077），服用前后两组Lysholm评分变化趋势（差值）差别存在统计学意义（P＜0.001）。结论口服胶原蛋白多肽能有效改善中老年女性膝骨关节炎患者的临床症状和功能，缓解疼痛，提高生活质量。
목적：관찰구복효원단백다태대중노년녀성슬골관절염환자관절동통화공능적림상효과。방법94례년령（60.79±7.57）세적중노년녀성슬골관절염환자수궤분성Peptan조46례화안위제조48례，분별복용효원단백다태（Peptan）8 g/d화맥아호정（안위제）8 g/d，련속복용3개월，응용WOMAC평분화Lysholm평분래평고복용전후골관절염증상화공능적개선상황。결과（1）WOMAC평분：복용전Peptan조화안위제조WOMAC평분차별무통계학의의（15.26±4.95여15.77±3.53，P＝0.565）；복용3개월후Peptan 조WOMAC평분명현감소도14.20±5.27（P＜0.001），이안위제조WOMAC평분15.79±3.53，여복용전차별무통계학의의（ P＝0.881）；복용전후량조WOMAC 평분변화추세（차치）차별존재통계학의의（ P＜0.001）；（2）Lysholm평분：복용전Peptan조화안위제조평분차별무통계학의의（80.24±11.78 vs 78.96±9.90，P＝0.569）；복용3개월후Peptan조Lysholm평분명현증가도82.63±10.49（P＜0.001），이안위제조Lysholm평분79.21±9.79，여복용전차별무통계학의의（P＝0.077），복용전후량조Lysholm평분변화추세（차치）차별존재통계학의의（P＜0.001）。결론구복효원단백다태능유효개선중노년녀성슬골관절염환자적림상증상화공능，완해동통，제고생활질량。
Objective To observe the clinical efficacy of oral medication of collagen peptides on knee osteoarthritis in middle -elderly women.Methods Ninety-four middle-elderly women with knee osteoarthritis , with an average age of 60.79 ±7.57 years old, were randomly divided into Peptan Group ( 46 cases ) and Placebo Group ( 48 cases ) .Patients in Peptan Group took collagen peptides Peptan 8g/d, while patients in Placebo Group took maltodextrin 8g/d for 3 months consecutively .The WOMAC score and Lysholm score were used to assess the improvement of the symptoms of osteoarthritis and function of knee before and after the treatment .Results WOMAC score in both Peptan Group and Placebo Group before the treatment showed no significant difference ( 15.26 ±4.95 vs. 15.77 ±3.53, P=0.565).After 3-month treatment, the WOMAC score in Peptan Group significantly reduced to 14.20 ±5.27 (P<0.001), while the WOMAC score in Placebo Group was 15.79 ±3.53, and no significant difference was observed comparing with that before the treatment ( P=0.881) .The changing trend of WOMAC score ( difference between the scores before and after the treatment ) showed statistically significant difference between Peptan Group and Placebo Group (P<0.001).Lysholm score in both Peptan Group and Placebo Group before the treatment showed no significant difference (80.24 ±11.78 vs.78.96 ±9.90, P=0.569).After 3-month treatment, the Lysholm score in Peptan Group significantly increased to 82.63 ±10.49 (P<0.001), while the Lysholm score in Placebo Group was 79.21 ±9.79, and no significant difference was observed comparing with that before the treatment (P=0.077). The changing trend of Lysholm score ( difference between the scores before and after the treatment ) showed statistically significant difference between Peptan Group and Placebo Group (P<0.001).Conclusion Oral medication of collagen peptides can significantly relieve joint pain and improve the quality of life in middle-elderly women with knee osteoarthritis .